Effects of Acute and Chronic Exercise on Myeloid-Derived Suppressor Cells in Melanoma Patients
NCT05615883 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16
Last updated 2024-10-15
Summary
This study is designed to investigate the effects of ketogenic milieu induced by acute exercise as well as the effects of recurrent exercise bouts on functional status and the accumulation in peripheral blood of MDSCs and the consequent balance on antitumor immunity in melanoma patients.
Conditions
Interventions
- OTHER
-
AEP Group Walking Sessions
The AEP Program consists in a single walking session on a treadmill lasting 80 minutes
- OTHER
-
CEP Group Walking Sessions
The chronic program consists in a walking session on a treadmill lasting 80 minutes (depending on the AEP results), repeated three time a week for three weeks.
Sponsors & Collaborators
-
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
lead OTHER
Principal Investigators
-
Licia Rivoltini, MD · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-01-20
- Primary Completion
- 2023-11-30
- Completion
- 2023-12-31
Countries
- Italy
Study Locations
More Related Trials
-
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
NCT06298734 ·Status: RECRUITING ·Phase: NA
-
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
NCT01213472 ·Status: COMPLETED ·Phase: PHASE1
-
Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma
NCT02673970 ·Status: RECRUITING
-
Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma
NCT00734188 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma
NCT00055562 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors
NCT01878396 ·Status: UNKNOWN
-
An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma
NCT02143999 ·Status: COMPLETED
-
Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel
NCT01666418 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.
NCT00057616 ·Status: COMPLETED ·Phase: PHASE3
-
The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma
NCT04357509 ·Status: UNKNOWN ·Phase: PHASE1
-
Studying the Clinical Trial Experiences of Patients With Mesothelioma
NCT05819580 ·Status: NOT_YET_RECRUITING
-
Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance
NCT03666325 ·Status: UNKNOWN ·Phase: PHASE2
-
Duration of Anti-PD-1 Therapy in Metastatic Melanoma
NCT02821013 ·Status: RECRUITING ·Phase: PHASE3
-
Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma Patients
NCT00559026 ·Status: COMPLETED ·Phase: PHASE1
-
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
NCT05358938 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Quality of Life and Physical Fitness After Immune Checkpoint Inhibitors
NCT03946007 ·Status: COMPLETED
-
Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma Study
NCT07050940 ·Status: RECRUITING ·Phase: NA
-
AMT-253 in Patients With Advanced Solid Tumours
NCT06209580 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases
NCT04793737 ·Status: RECRUITING ·Phase: NA
-
Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases
NCT05903937 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00002669 ·Status: COMPLETED ·Phase: PHASE2
-
Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients
NCT00287131 ·Status: UNKNOWN ·Phase: PHASE2
-
Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma Management
NCT06627595 ·Status: RECRUITING
-
Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases
NCT04812470 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma
NCT00942162 ·Status: COMPLETED ·Phase: PHASE2